SCHEMBL5026183

SCHEMBL5026183

CCOC(=O)c1sc2nc(-c3ccncc3)nc(-c3cccc([N+](=O)[O-])c3)c2c1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.54
RAB9A P51151 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
PDE4B Q07343 2/20 0.51
PDE4D Q08499 2/20 0.51
PDE4A P27815 1/20 0.51
PDE4C Q08493 1/20 0.51
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 4/20 0.49
MAPK1 P28482 2/20 0.49
GAA P10253 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GLA P06280 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
ATM Q13315 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4420397 0.94 MAPT (0.56) MAPTRAB9AMEN1KMT2APDE4B
SCHEMBL5024695 0.88 MAPT (0.54) MAPTRAB9AMEN1KMT2APDE4B
SCHEMBL5026177 0.88 KDM4E (0.54) MAPTRAB9AMEN1KMT2APDE4B
SCHEMBL27517855 0.87 MAPT (0.46) MAPTRAB9AMEN1KMT2APDE4B
SCHEMBL6217826 0.86 LHCGR (0.54) MAPTRAB9AMEN1KMT2APDE4B
SCHEMBL5026135 0.86 MAPT (0.52) MAPTRAB9AMEN1KMT2APDE4B
SCHEMBL6215827 0.86 KDM4E (0.60) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL4426414 0.84 LHCGR (0.57) MAPTRAB9AMEN1KMT2APDE4B
SCHEMBL4418734 0.81 KDM4E (0.62) MAPTRAB9AMEN1KMT2APDE4B
SCHEMBL5043443 0.81 MAPT (0.47) MAPTRAB9AMEN1KMT2APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7375109-B2 Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity N.V. ORGANON (NL) 2008-05-20 US disclosed
EP-1427734-B1 GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY AKZO NOBEL NV (NL) 2005-11-09 EP disclosed
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity MERCK SHARP & DOHME B.V. (NL) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity FSHR, GNRHR, LHCGR MAPT 4881/4885RAB9A 4450/4885MEN1 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.